Alector ALEC
Alector Q2 FY25: revenue $7.9M, down 48%; diluted EPS −$0.30
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-25-105050
- Document
- 10-Q
- Exhibit 10.1
- Material contract
Key figures from this report
These are the numbers Alector reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$7.9M−48% from $15.1M in Q2 FY2410-Q income statement, on EDGAR
- Net income−$30.5MAgainst −$38.7M in Q2 FY2410-Q income statement, on EDGAR
- Diluted EPS−$0.30Against −$0.40 in Q2 FY2410-Q income statement, on EDGAR
- Cash and cash equivalents$44.8M−6% from $47.5M in Q2 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$49.0MAgainst −$62.8M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
- Fate Therapeutics FATE public float $113M, Jun 30, 2025
- Caribou Biosciences CRBU public float $113M, Jun 30, 2025
- Protara Therapeutics PRTO public float $112M, Jun 30, 2025
- TuHURA Biosciences HURA public float $111M, Jun 30, 2025
